TITLE:
Endometrial Thermoablation with Novasure® for the Treatment of Abnormal Uterine Bleeding in the Obstetrics and Gynecology Department of the Hospital Center of Nevers, France from 2019 to 2022
AUTHORS:
Eléonore Gbary-Lagaud, Carine Houphouet-Mwandji, José Loba, Denis Effoh, Roland Adjoby, Rémi Kosi-Tuavawa
KEYWORDS:
Anormal Uterine Bleeding, Endometrial Thermoablation, Quality of Life
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.15 No.3,
March
24,
2025
ABSTRACT: Introduction: Anormal uterine bleeding is a situation that disrupts genital life. Extreme cases can be life-threatening. Several treatments are available, including thermoablation of the endometrium using the Novasure® procedure. Objective: This paper aims to describe the results of treatment of anormal uterine bleeding with Novasure® thermoablation. Method: This was a descriptive and analytical study which took place from November 1, 2019 to December 31, 2022 at the Centre Hospitalier de l'Agglomération de Nevers, France. All patients diagnosed with anormal uterine bleeding after ruling out an organic cause with a Higham score > 150 constituted the study population. Patients included in the study were those treated by endometrial thermoablation. Incomplete files and patients who continued postoperative follow-up in another health facility were not included in the study. A Novak cannula endometrial biopsy was performed each time. We were interested in the following variables: qualitative (profession, medical treatment received, favouring factors, endometrial histology, postoperative evolution), and quantitative (age, parity, intraoperative uterine cavity measurements). It should be noted that all patients no longer wished to have children. Results: During the study period, we selected 156 patients with HUF, including 17 (10.90%) treated by Novasure® thermoablation. The patients were over 40 years of age in 64.7% of cases. Contributing factors were dysthyroidism, dysovulation and anticoagulant use (11.8%). Failure of medical treatment was the indication for thermoablation in 81.82% of cases. Patients were fully satisfied, with complete reversal of signs in 82.36% of cases. Simple glandular hyperplasia without atypia was present in 52.94% of cases. Conclusion: Endometrial thermoablation is an effective way of overcoming abnormal uterine bledding with very few complications. Anormal uterine bleeding can be stopped immediately, often with a marked improvement in quality of life. A large uterine cavity is a major factor limiting its effectiveness. The high cost of the device is the main factor limiting its widespread use.